142 related articles for article (PubMed ID: 27127159)
1. Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine.
Numata K; Morinaga S; Katayama Y; Sawazaki S; Numata M; Godai T; Higuchi A; Shiozawa M; Rino Y; Masuda M; Akaike M
Anticancer Res; 2016 May; 36(5):2467-74. PubMed ID: 27127159
[TBL] [Abstract][Full Text] [Related]
2. Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery.
Morinaga S; Murakawa M; Katayama Y; Yamaoku K; Aoyama T; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M
Anticancer Res; 2015 Sep; 35(9):4865-70. PubMed ID: 26254380
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
4. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
[TBL] [Abstract][Full Text] [Related]
5. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Wasan HS; Springett GM; Chodkiewicz C; Wong R; Maurel J; Barone C; Rosbrook B; Ricart AD; Kim S; Spano JP
Br J Cancer; 2009 Oct; 101(7):1162-7. PubMed ID: 19724276
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Takahashi H; Yamada D; Asukai K; Wada H; Hasegawa S; Hara H; Shinno N; Ushigome H; Haraguchi N; Sugimura K; Yamamoto K; Nishimura J; Yasui M; Omori T; Miyata H; Ohue M; Yano M; Sakon M; Ishikawa O
Pancreatology; 2020 Jul; 20(5):919-928. PubMed ID: 32563596
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
8. The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer.
Shimoda M; Katoh M; Kita J; Sawada T; Kubota K
Chemotherapy; 2010; 56(6):501-6. PubMed ID: 21099223
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.
Vainshtein JM; Schipper M; Zalupski MM; Lawrence TS; Abrams R; Francis IR; Khan G; Leslie W; Ben-Josef E
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):96-101. PubMed ID: 23265573
[TBL] [Abstract][Full Text] [Related]
10. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Ko AH; Hwang J; Venook AP; Abbruzzese JL; Bergsland EK; Tempero MA
Br J Cancer; 2005 Jul; 93(2):195-9. PubMed ID: 15999098
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9.
Klapdor R; Klapdor S; Bahlo M
Anticancer Res; 2012 May; 32(5):2191-7. PubMed ID: 22593509
[TBL] [Abstract][Full Text] [Related]
12. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Xie H; Jiang W; Xiao SY; Liu X
J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Saad ED; Machado MC; Wajsbrot D; Abramoff R; Hoff PM; Tabacof J; Katz A; Simon SD; Gansl RC
Int J Gastrointest Cancer; 2002; 32(1):35-41. PubMed ID: 12630768
[TBL] [Abstract][Full Text] [Related]
14. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
16. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
Asia Pac J Clin Oncol; 2010 Jun; 6(2):98-105. PubMed ID: 20565421
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Tas F; Karabulut S; Ciftci R; Sen F; Sakar B; Disci R; Duranyildiz D
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1163-71. PubMed ID: 24647734
[TBL] [Abstract][Full Text] [Related]
19. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]